IPM Take
MS care has become highly sophisticated at selecting disease-modifying therapies, but it is still too passive about preventing avoidable complications around them. Herpes zoster is not a small inconvenience for people with MS, especially when immune-modulating treatment, age, disability and comorbidity can increase vulnerability.
The new recombinant zoster vaccine data are not glamorous, but they are politically important. Prevention is not a side task. It is part of safe personalised neurology, and the system should be judged not only by which high-cost therapy it prescribes, but by whether it protects patients from predictable harms.
Executive Summary
A claims-based retrospective cohort study in adults with multiple sclerosis assessed the effectiveness of recombinant zoster vaccine against herpes zoster in the United States.
Public reporting of the study describes more than 71,000 patients across Medicare and commercial insurance claims. Two-dose recombinant zoster vaccination was associated with a 64% to 81% reduction in shingles risk among adults with MS, depending on insurer group and analysis.
The findings support vaccination as a practical prevention strategy in a population with elevated shingles risk. The study is observational, so residual confounding and claims-data limitations remain possible. It does not replace clinical judgement on vaccination timing, disease-modifying therapy sequencing or individual immune status.
Why it matters
- Patients / advocates: Preventing shingles can mean avoiding pain, complications, treatment interruption and additional disability burden.
- Clinicians: Vaccination planning should be built into MS treatment pathways before immune-modifying therapies narrow the window.
- Public authorities: Vaccine access in chronic neurological disease is an implementation issue, not only a patient responsibility.
- Hospitals / providers: Neurology clinics need systematic prompts, referral mechanisms and documentation to make vaccination routine.
Cancer care is no longer organised only around tumour site and stage. It is increasingly organised around the biological information that tells clinicians what the tumour is doing and which options may be available.
That makes sequencing infrastructure a quiet but decisive access issue. A RAS inhibitor, an ADC strategy, a ctDNA-guided switch or a trial match may all depend on whether genomic information exists in time. If the result arrives after treatment has already started, the system has already lost part of the value.
The policy question is therefore practical: who gets sequenced, when, where and at whose cost? Comprehensive genomic solutions can support earlier and better decisions, but only if they are connected to referral rules, reimbursement, laboratory capacity and clinical interpretation.
For IPM, the message is simple. The precision oncology race is not only about drugs. It is about whether health systems can build the genomic operating system that makes those drugs usableMultiple sclerosis care is now full of complex decisions. Clinicians weigh efficacy, relapse risk, disability progression, pregnancy, infection risk, MRI activity, age, patient preference and long-term sequencing. Yet some of the most practical prevention steps still risk being treated as administrative details rather than essential parts of care.
Herpes zoster prevention belongs in that conversation. Shingles can cause severe pain, postherpetic neuralgia, treatment disruption and avoidable healthcare use. For people already managing MS symptoms, fatigue, mobility problems and immune-modulating therapy decisions, a preventable infection is not a minor event. It is another burden layered onto a chronic disease.
The new real-world data strengthen the case for making recombinant zoster vaccination routine where clinically appropriate. A large claims-based study cannot eliminate every bias, but its scale and effect size make the implementation question harder to ignore. If vaccination reduces shingles risk substantially in adults with MS, then the failure to plan vaccination becomes part of the access and quality problem.
This is not about blaming patients for missing a vaccine. It is about whether the system prompts, counsels, records and follows through. Too often, vaccination is left to chance between neurologists, primary care, pharmacies and insurers. That fragmentation is exactly how preventable risk survives in modern care.
For IPM, the policy message is simple: sophisticated MS therapy should come with sophisticated prevention infrastructure. Precision neurology should not stop at choosing the next disease-modifying drug. It should also prevent the harms that the system can see coming.
